Pliant Sees Treating Fibrosis As Primary Goal, Not Add-On
This article was originally published in Start Up
Executive Summary
The start-up will advance UCSF research on fibrosis to improve upon current treatments for idiopathic pulmonary fibrosis, and possibly create therapeutics for fibrosis of the liver, kidneys and GI tract as well.
You may also be interested in...
Esbriet, Ofev Reviews Convinced FDA Of Acceptable IPF Endpoint
FDA leaders explain in NEJM how they came to accept a measure of lung function as a surrogate for mortality in trials of idiopathic pulmonary fibrosis therapies. See how agency reviewers handled this in a preview of our upcoming Drug Review Profile series.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.